Ginkgo Bioworks Holdings, Inc.

What they do

Ginkgo operates in two segments: cell engineering and biosecurity. Cell engineering provides biological R&D services (solutions) and tools (automation, data, and IP licenses) to help customers engineer cells for medicine, agriculture, industrial biotech, and government programs. Biosecurity offers services to identify and monitor biological threats. The company does not make end products; it enables customers' R&D and retains potential downstream value share (milestones, royalties, equity) on some programs.

Revenue drivers

• Cell engineering solutions — Custom R&D programs with fixed fees for scoped work, plus technical milestones; historically multi-year and make up a large portion of revenue. Revenue declined in 2025 as programs were rationalized.
• Cell engineering tools — Launched in 2024: RAC automation systems, Datapoints data packages, and IP licenses (host cells, metagenomic library). Fees for RAC systems are earned over 6-12 months; Datapoints over shorter periods.
• Biosecurity — Services to detect and monitor biological threats for government and commercial customers. Revenue contribution has declined with the end of major COVID-era contracts (2021 revenue $313.8M fell to $170.2M by 2025, driven partly by biosecurity decline).

Recent performance

For Q2 2026 (quarter ended June 30, 2026), revenue was $20.2M, down 48% from $39M in the prior-year quarter, primarily due to program rationalization from restructuring. GAAP net loss from continuing operations was $57M, wider than the $53M loss a year earlier. Adjusted EBITDA was -$36M, down from -$25M. Cash, cash equivalents, and marketable securities were $302M as of June 30, 2026. Full-year 2025 revenue was $170.2M with a net loss of $313,000, and operating cash flow was -$171.1M.

Strategy

Management is pivoting to become a provider of autonomous lab infrastructure, scaling Nebula, its Boston-based cloud lab, with RAC systems and AI/ML-driven data generation. It is pursuing government contracts to build autonomous labs for NSF nodes and federal agencies, aiming to onshore R&D for U.S. biopharma. The company is expanding its tools offerings (RACs, Datapoints, ADME-One) and shifting downstream value share from equity to milestones and royalties. It is also executing restructuring actions from 2024 to reduce costs and narrow cash burn.

Risks

• History of losses — Ginkgo has had significant net losses and an accumulated deficit of $6.2 billion as of December 31, 2025, with no guarantee of future profitability.
• Dependence on uncertain downstream value — Milestone, royalty, and equity payments from customer programs are uncertain and contingent on customers' successful commercialization, which is outside Ginkgo's control.
• Revenue volatility and program rationalization — Revenue has declined sharply from $477.7M in 2022 to $170.2M in 2025, and ongoing restructuring could reduce near-term revenue further.
• Customer concentration and government reliance — A significant portion of revenue comes from biosecurity and government contracts, which are exposed to policy changes, shutdowns, and shifts in federal priorities.

Outlook

Management reaffirmed 2026 total cash burn guidance of $150M to $125M. They are scaling Nebula, which they state is the world's largest autonomous lab, adding over 100 robots and ramping new protocols weekly. They expect to continue winning government contracts and expanding pharma services, such as ADME-One, which they claim is 10x cheaper than WuXi and signed 17 customers in six weeks. The outlook assumes further growth in autonomous lab demand and successful execution of strategic restructuring.